Novogen (NASDAQ:KZIA) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Novogen (NASDAQ:KZIA – Free Report) from a sell rating to a hold rating in a research report released on Friday.

KZIA has been the topic of a number of other reports. HC Wainwright upgraded shares of Novogen from a “buy” rating to a “strong-buy” rating and set a $13.00 price objective on the stock in a research note on Thursday, July 10th. Maxim Group reissued a “buy” rating and set a $15.00 target price on shares of Novogen in a report on Wednesday, June 11th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat, Novogen has an average rating of “Strong Buy” and a consensus target price of $14.00.

Read Our Latest Report on KZIA

Novogen Trading Down 4.1%

NASDAQ KZIA opened at $7.76 on Friday. Novogen has a 12 month low of $2.86 and a 12 month high of $39.05. The company’s fifty day moving average price is $8.40 and its two-hundred day moving average price is $5.94.

Institutional Trading of Novogen

An institutional investor recently bought a new position in Novogen stock. Barclays PLC acquired a new position in Novogen Limited (NASDAQ:KZIA – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned 2.38% of Novogen as of its most recent SEC filing. 30.89% of the stock is currently owned by institutional investors and hedge funds.

Novogen Company Profile

(Get Free Report)

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.

See Also